# Ruxolitinib for Cancer Cachexia

> **NCT04906746** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Tu Dan** · enrollment: 10 (actual)

## Conditions studied

- Stage IV Non-small Cell Lung Cancer
- Cachexia

## Interventions

- **DRUG:** Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.

## Key facts

- **NCT ID:** NCT04906746
- **Lead sponsor:** Tu Dan
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-23
- **Primary completion:** 2024-09-27
- **Final completion:** 2025-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906746, "Ruxolitinib for Cancer Cachexia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04906746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*